Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 3 drugs
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Synonyms: … Empagliflozin
Matched Name: … Empagliflozin
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it ... Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily …
Matched Categories: … linagliptin and empagliflozin ... metformin and empagliflozin ... empagliflozin ... Alimentary Tract and Metabolism …
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin...
Approved
Matched Description: … Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management ... It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and ... [A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval …
Matched Mixtures name: … Glyburide and Metformin ... Glyburide and Metformin ... Glyburide and Metformin …
Matched Categories: … metformin and linagliptin ... metformin and empagliflozin ... metformin and acarbose ... Alimentary Tract and Metabolism ... metformin and evogliptin …
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Synonyms: … Linagliptin
Matched Name: … Linagliptin
Matched Description: … is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 ... Linagliptin was approved by the FDA on May 2, 2011[L9557]. ... Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Matched Categories: … linagliptin and empagliflozin ... metformin and linagliptin ... linagliptin ... Alimentary Tract and Metabolism ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … LINAGLIPTIN EG ... LINAGLIPTIN INTAS ... Linagliptin STADA 5 mg Filmtabletten …
Displaying all 3 drugs